Lupin Ltd (BSE: 500257) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹89,426 Cr, it ranks #124 by market cap among the 6,137 Indian listed companies on FinBizNet, and #8 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,928.90 (as of 25 Oct 2026), the share price is 23.7% below its 52-week high of ₹2,529.50 and 1.9% above its 52-week low of ₹1,892.90. The share price is down 1.1% over one year and down 18.6% over three months.
| Current Price | ₹1,928.90 |
|---|---|
| Market Cap | ₹89,426 Cr |
| BSE Code | 500257 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 16.6 |
| Return on Equity | 26.91% |
| Return on Assets | 12.71% |
| 52-Week Range | ₹1,892.90 – ₹2,529.50 |
| 1-Year Price Change | -1.1% |
| 3-Month Price Change | -18.6% |
| Beta (1Y) | 0.21 |
| Dividend Yield | 0.93% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.lupin.com |
| Revenue | ₹8,277 Cr |
|---|---|
| Net Profit | ₹1,417 Cr |
| Net Margin | 17.1% |
| EPS (Basic) | ₹30.95 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women’s health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro
1. Pharmaceuticals-This segment manufactures and sells pharmaceuticals.
1. Pharmaceuticals-99.5% 2. Others-0.5%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Glenmark Pharmaceuticals Limited | ₹62,838 Cr | 45.7 | 14.07% | ₹4,018 Cr | +16.2% |
Listed by market capitalisation. Ratios are shown for context only.
Lupin Ltd is trading at ₹1,928.90, with a market capitalisation of ₹89,426 Cr.
Lupin Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Lupin Ltd has a P/E of 16.6 and a return on equity of 26.91%.
Lupin Ltd is listed on the BSE under the scrip code 500257.
Lupin Ltd's share price is down 1.1% over one year and down 18.6% over three months. Its 52-week range is ₹1,892.90 to ₹2,529.50.
In Q1 FY27, Lupin Ltd reported revenue of ₹8,277 Cr and net profit of ₹1,417 Cr, with basic EPS of ₹30.95 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.